A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -49.29% this year. Over the last six months, there has been a stronger performance of -65.83%. The price of SKYE leaped by -28.25% during the last 30 days period. For the last 5-days stocks have improved 7.09%.
Skye Bioscience Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $17.65 on 04/18/24, while the lowest value for the same period was recorded at $1.14 on 04/08/25.
52-week price history of SKYE Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Skye Bioscience Inc’s current trading price is -91.87% away from its 52-week high, while its distance from the 52-week low is 25.88%. The stock’s price range during this period has varied between$1.14 and $17.65. The Skye Bioscience Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.58 million for the day, a figure considerably lower than their average daily volume of 0.66 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Skye Bioscience Inc (SKYE) has experienced a quarterly decline of -46.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 44.45M and boasts a workforce of 16 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.7601, with a change in price of -2.8450. Similarly, Skye Bioscience Inc recorded 476,010 in trading volume during the last 100 days, posting a change of -66.47%.
SKYE’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SKYE stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
SKYE Stock Stochastic Average
As of today, Skye Bioscience Inc’s raw stochastic average for the last 50 days stands at 11.40%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 11.40%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 16.81% and 17.27%, respectively.
